SCHEMBL4475776

SCHEMBL4475776

COc1ccc2c(c1)OCC(=O)N2Cc1cc(Cl)cc(N2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
BACE1 P56817 1/20 0.42
UTS2R Q9UKP6 3/20 0.41
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SLC2A1 P11166 1/20 0.39
TP53 P04637 1/20 0.39
KDM1A O60341 1/20 0.39
ALOX15 P16050 1/20 0.38
CBX7 O95931 1/20 0.38
CDYL2 Q8N8U2 1/20 0.38
CDYL Q9Y232 1/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.38
F10 P00742 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPK3 P27361 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13973049 0.89 SMN1; SMN2 (0.43) L3MBTL1SMN1; SMN2MAPTLMNAUTS2R
SCHEMBL4477885 0.83 L3MBTL1 (0.52) L3MBTL1ALOX15CBX7CDYL2CDYL
SCHEMBL12110188 0.78 L3MBTL1 (0.53) L3MBTL1SMN1; SMN2MAPTLMNAUTS2R
SCHEMBL4477873 0.77 L3MBTL1 (0.58) L3MBTL1MAPTALOX15CBX7CDYL2
SCHEMBL4489307 0.75 DRD2 (0.49) SMN1; SMN2MAPTLMNASLC2A1
SCHEMBL12110060 0.74 L3MBTL1 (0.43) L3MBTL1ALOX15CBX7CDYL2CDYL
SCHEMBL12106734 0.74 UTS2R (0.44) L3MBTL1SMN1; SMN2UTS2RHTTNPSR1
SCHEMBL1294574 0.73 UTS2R (0.45) L3MBTL1SMN1; SMN2UTS2RHTTNPSR1
SCHEMBL1294844 0.71 GAA (0.45) L3MBTL1MAPTLMNAUTS2RNPSR1
SCHEMBL14202062 0.71 HTR6 (0.47) L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476675-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2009-01-13 US disclosed
EP-1603880-B1 QUINOLINONE/BENZOXAZINONE DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2008-05-07 EP disclosed
US-20050261308-A1 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC 2005-11-24 US disclosed
US-6943169-B2 Quinolinone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2005-09-13 US disclosed
US-20040186092-A1 Quinolinone derivaties and uses thereof ROCHE PALO ALTO LLC 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186092-A1 Quinolinone derivaties and uses thereof NQO2, UGT1A8, UGT1A1 L3MBTL1 4557/4885SMN1; SMN2 3996/4885MAPT 4044/4885
US-20050261308-A1 Quinolinone derivatives and uses thereof RECQL, NQO2, QRFPR L3MBTL1 4043/4885SMN1; SMN2 3556/4885MAPT 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.